Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Siemens Showcases Broad Portfolio of Infectious Disease Testing Capabilities at ECCMID 2012

Published: Monday, April 16, 2012
Last Updated: Monday, April 16, 2012
Bookmark and Share
Company exhibit featured the latest in liver health, microbiology and molecular diagnostic solutions.

Siemens Healthcare Diagnostics has showcased its broad portfolio of infectious disease testing capabilities¹ — from screening and diagnosis to susceptibility testing, genotyping, therapy selection and monitoring — at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in London. The Siemens solutions on display at ECCMID 2012 reinforced the company's commitment to the development of reliable, high-quality infectious disease diagnostic solutions to help laboratories optimise workflow and enhance operational efficiency.

The exhibit — themed “Innovation. Powered for Infectious Disease Solutions.”— featured innovative products designed to address the current and growing demands of infectious disease testing, including customised workflow options, assays to help clinicians improve patient care, and clinically-validated, expert-based software solutions that support personalised medicine.

“Infectious disease is a leading cause of death worldwide2, making it critical that clinicians have access to diagnostic solutions that provide trustworthy results, which ultimately contribute to optimal patient outcomes,” said Christoph Gauer, PhD, CEO, Molecular and Microbiology Business Segment at Siemens Healthcare Diagnostics. “Visitors to our ECCMID booth learnt how Siemens can help them improve the delivery of vital information healthcare providers require to care for their patients impacted by infectious disease.”

Liver Health Solutions

The Siemens ECCMID exhibit provided a platform to showcase the company’s portfolio of diagnostic solutions for managing liver-disease patients, including routine chemistry tests, hepatitis serology assays, viral load testing and ultrasound systems. A key highlight was the recently launched ADVIA Centaur® ELF™ Test3, the first routine standardised direct biomarker panel for the assessment of liver fibrosis, a leading indicator of chronic liver disease, such as cirrhosis and liver cancer. With results provided in about an hour, the ELF test combines three serum biomarkers—hyaluronic acid (HA), Procollagen III amino terminal peptide (PIIINP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)—which provide a score, shown to correlate to the level of liver fibrosis as assessed by liver biopsy. In an international multi-centre study with a mix of patient groups, the ELF test was clinically validated and found to be accurate to differentiate mild, moderate and severe fibrosis4.

Microbiology Solutions

Attendees also learnt about Siemens’ latest microbiology offerings, including LabPro Connect, a new software solution that consolidates databases for multiple testing systems. The open-system configuration option delivers workstation networking by aggregating LabPro ID/AST data to bench and laboratory office computers, reducing wasted staff time absorbed by visiting different instruments to collect information. LabPro Connect can also be configured as a closed-system without workstation networking.

Also highlighted were microbiology automation and mass spectrometry solutions now available from Siemens as a result of a recently forged strategic partnership with Copan and co-marketing agreement with Bruker Corporation. The Copan Walk-Away Specimen Processor (WASP® instrument)5 offers fully automated bacteriology specimen processing, individualised sample management, utilising familiar streaking patterns, standardises workflow processes and optimises specimen set-up activities to free up staff resources. The Bruker MALDI Biotyper6 provides faster, more accurate and very cost-effective molecular microorganism identification using MALDI-TOF mass spectrometry for proteomic fingerprinting. This technology provides faster TTR, along with outstanding accuracy and sensitivity, to meet the demands of diverse laboratory needs.

Molecular Solutions

Additionally, Siemens’ ECCMID booth included information about the VERSANT® HCV RNA 1.0 Assay, a highly sensitive viral load assay for the VERSANT kPCR Molecular System7. This assay aids in the management of individuals infected with hepatitis C (HCV)—one of the main causes of chronic liver disease worldwide8— who are undergoing antiviral therapy. This assay provides outstanding precision across the dynamic range and 100% specificity with a 95% lower confidence limit of 99.7%, and features technology that is compatible with all HCV genotypes.

Visitors also found out about TRUGENE® HIV-1 GuideLines™ 17.09, the latest interpretive algorithm for HIV-1 drug resistance, which are clinically validated and updated annually by an independent expert panel, as well as the company’s latest tissue preparation and extraction solutions to maximise lab efficiency.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Preparing for Potential Zika Outbreaks
Experts at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are developing tools to monitor the spread of the Zika virus and are conducting research to gather more solid data to better assess the risks associated with the infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!